8-K: Collegium Secures $980M Credit Facility, Refinances Debt

Collegium Pharmaceutical closed a new $980 million syndicated credit facility, refinancing existing debt and securing capital for future growth.

Summary

• Collegium Pharmaceutical, Inc. entered into a new Credit Agreement on December 23, 2025, establishing a new syndicated credit facility.
• The new facility totals $980,000,000, consisting of a $580,000,000 initial Term Loan, $300,000,000 in delayed draw term loan commitments, and a $100,000,000 revolving credit facility.
• The initial Term Loan was used to repay approximately $581,000,000 of principal, representing the entire remaining balance of the previous $646,000,000 term loan (Existing Credit Agreement) from Pharmakon Advisors, LP.
• The new credit facility matures in 2030.
• Loans under the new Credit Agreement will bear interest at an annual rate equal to the term Secured Overnight Financing Rate (SOFR) plus a spread ranging from 2.75% to 3.75%, based on the Company's First Lien Net Leverage Ratio. The initial interest rate upon closing was SOFR plus 2.75%.
• The delayed draw term loan and revolving credit facility were undrawn at closing and are expected to be used for general corporate purposes, including partially funding future business development opportunities.
• The Company is obligated to repay the loans in scheduled quarterly installments, commencing on March 31, 2026.
• The Credit Agreement includes quarterly tested financial covenants: a first lien secured net leverage ratio maintenance covenant (allowing the Company to net up to $250,000,000 of unrestricted cash and cash equivalents) and a customary fixed charge coverage ratio maintenance covenant.
• Upon repayment of the Existing Credit Agreement, all outstanding obligations, including applicable prepayment premium and make-whole amount, were paid in full, and all commitments, liens, and security interests were terminated.
• A press release announcing the closing of the credit facility was issued on December 30, 2025.

Sentiment

Score: 8

Explanation: The filing details a successful refinancing that significantly improves debt terms, reduces interest costs, and provides substantial flexible capital for future growth and business development, indicating a strong positive financial move.

Positives

• Secured a new $980 million syndicated credit facility with a favorable five-year maturity (2030).
• Significantly improves debt terms and is expected to result in meaningful annualized interest savings due to a reduced interest rate (initial SOFR plus 2.75%).
• Provides substantial additional capital and flexibility for general corporate purposes and future business development opportunities.
• The delayed draw term loan and revolving credit facility were undrawn at closing, offering significant liquidity and strategic optionality.
• Transitioned from a specialized lender to a syndicated bank facility, indicating increased financial maturity and market confidence.

Negatives

• Incurred a prepayment premium and make-whole amount to terminate the previous Existing Credit Agreement, representing a cost of early repayment.
• The company is subject to new financial covenants (first lien secured net leverage ratio and fixed charge coverage ratio) which could impose restrictions on future financial operations.

Risks

• Unknown liabilities.
• Risks related to future opportunities and plans for products, including uncertainty of expected financial performance.
• Ability to commercialize and grow sales of products.
• Ability to manage relationships with licensors.
• Success of competing products that are or become available.
• Ability to maintain regulatory approval of products, and any related restrictions, limitations, and/or warnings in the label of products.
• Size of the markets for products, and ability to service those markets.
• Ability to obtain reimbursement and third-party payor contracts for products.
• Rate and degree of market acceptance of products.
• Costs of commercialization activities, including marketing, sales and distribution.
• Changing market conditions for products.
• Outcome of any patent infringement or other litigation that may be brought by or against us.
• Outcome of any governmental investigation related to our business.
• Ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory.
• Ability to obtain funding for our operations and business development.
• Regulatory developments in the U.S.
• Expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products.
• Ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance.
• Customer concentration.
• Accuracy of estimates regarding expenses, revenue, capital requirements and need for additional financing.

Future Outlook

The new credit facility is expected to result in meaningful annualized interest savings and provides significant flexibility and additional capital to fund future business development opportunities. The company aims to expand and diversify its product portfolio, with Jornay PM identified as a lead growth driver, to further drive long-term value.

Management Comments

• "We are pleased to have successfully closed our inaugural syndicated credit facility which significantly improves our debt terms and underscores the strength of our financial outlook." Colleen Tupper, Chief Financial Officer.
• "This additional capital also provides us with flexibility to further drive long-term value as we continue to evaluate opportunities to expand and diversify our product portfolio through business development." Colleen Tupper, Chief Financial Officer.

Industry Context

This move reflects a common strategy in the biopharmaceutical industry for established companies to optimize their capital structure, reduce financing costs, and secure flexible capital for strategic initiatives like M&A or product portfolio expansion. The shift from a specific lender (Pharmakon Advisors) to a syndicated bank facility suggests increased financial maturity and market confidence in Collegium, aligning with broader industry trends for growing companies to access more diverse and often more favorable financing sources.

Comparison to Industry Standards

• The transition from a specialized biopharma credit provider (Pharmakon Advisors) to a syndicated bank facility (led by Truist Bank with several other major banks) is typical for growing biopharmaceutical companies as they achieve greater scale and financial stability, often resulting in more favorable terms.
• Interest rates tied to SOFR plus a spread are standard for corporate credit facilities in the current market environment. A spread of 2.75% to 3.75% (with an initial 2.75%) for a first lien secured facility is competitive, especially for a company in the biopharmaceutical sector which can sometimes face higher borrowing costs due to inherent industry risks.
• The inclusion of a delayed draw term loan and revolving credit facility provides flexible capital similar to what many established companies use for opportunistic M&A or working capital needs, aligning with best practices for strategic financial management.

Corporate Governance

Stakeholder Impact

• Shareholders: Expected to benefit from reduced interest expenses, improved financial flexibility, and potential for future growth through business development, which could lead to increased shareholder value.
• Creditors (New): The new syndicate of banks (Truist Bank, Citizens Bank, MUFG Bank, etc.) are now the primary lenders, benefiting from interest payments and security interests under the new agreement.
• Creditors (Previous): Pharmakon Advisors, LP, had their outstanding obligations repaid in full, including prepayment premium and make-whole amount, terminating their relationship.
• Management: Gains greater financial flexibility to pursue strategic initiatives and manage the company's debt more efficiently.

Next Steps

• Commence scheduled quarterly loan installments under the new Credit Agreement on March 31, 2026.
• File the full text of the Credit Agreement as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.
• Continue to evaluate opportunities to expand and diversify the product portfolio through business development.
• Grow the commercial portfolio, with Jornay PM as the lead growth driver.

Key Dates

Recommendation

The successful refinancing at significantly improved terms, coupled with the securing of substantial flexible capital for strategic growth initiatives, materially strengthens Collegium's financial position and future prospects. The reduction in interest expense will directly boost profitability, while the undrawn delayed draw and revolving facilities provide a strong war chest for accretive business development, signaling a positive trajectory for long-term value creation.

Keywords

Collegium Pharmaceutical, COLL, credit facility, debt refinancing, syndicated loan, term loan, revolving credit, SOFR, biopharmaceutical, corporate finance, capital structure, business development, financial outlook, NASDAQ